Physician profile
Karen F Schwartz
NPI 1225119241
$278,044.61
in general payments reported to CMS, 2019-2025
68 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $44K · 2021: $15K · 2022: $35K · 2023: $37K · 2024: $43K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Travel and Lodging: $10K · Food and Beverage: $8,480 · Honoraria: $500 · Education: $182 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,250.00 |
| Travel and Lodging | $10,393.97 |
| Food and Beverage | $8,480.23 |
| Honoraria | $500.00 |
| Education | $181.76 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $237,676.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $16,839.48 | 2023-2025 | Veozah |
| Amag Pharmaceuticals, INC. | $4,203.41 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,258.60 | 2021-2025 | |
| Insulet Corporation | $1,804.25 | 2019-2023 | Omnipod |
| Amgen INC. | $1,700.47 | 2019-2025 | Evenity, Tepezza, Prolia |
| Amneal Pharmaceuticals LLC | $1,629.24 | 2019-2025 | Unithroid |
| Novo Nordisk INC | $1,336.10 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,284.83 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Radius Health, INC. | $1,207.43 | 2019-2025 | Tymlos |
| Abbvie INC. | $1,011.39 | 2019-2025 | Synthroid |
| Sanofi-Aventis U.S. LLC | $947.38 | 2019-2024 | |
| Mannkind Corporation | $863.02 | 2019-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $545.23 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $519.11 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.